Schweitzer N, Vogel A
Department of Gastroenterology, Hepatology and Endcrinology, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
Department of Gastroenterology, Hepatology and Endcrinology, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):345-53. doi: 10.1016/j.bpg.2015.01.002. Epub 2015 Feb 19.
Cholangiocarcinomas (CCA) are rare tumors of the liver with poor prognosis. The standard of care in patients with unresectable tumors or metastatic disease is combination chemotherapy (CT) with gemcitabine and cisplatin. Targeted therapies inhibiting EGFR, VEGF, MEK and others are broadly tested in CCA but to date, the existing data from randomized and nonrandomized trials do not justify the application of small molecules outside of clinical trials. In clinical practice, many patients receive second-line CT after failure of gemcitabine/cisplatin, although there is so far no evidence to support second-line CT. This review summarizes current chemotherapy protocols and ongoing studies, including conventional chemotherapy and targeted therapies.
胆管癌（CCA）是一种预后较差的罕见肝脏肿瘤。对于无法切除的肿瘤或转移性疾病患者，标准治疗方案是吉西他滨和顺铂联合化疗（CT）。在CCA中广泛测试了抑制表皮生长因子受体（EGFR）、血管内皮生长因子（VEGF）、丝裂原活化蛋白激酶（MEK）等的靶向治疗，但迄今为止，来自随机和非随机试验的现有数据并不足以证明在临床试验之外应用小分子药物的合理性。在临床实践中，许多患者在吉西他滨/顺铂治疗失败后接受二线CT治疗，尽管目前尚无证据支持二线CT治疗。本综述总结了当前的化疗方案和正在进行的研究，包括传统化疗和靶向治疗。
